BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15946992)

  • 1. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
    Maier TJ; Janssen A; Schmidt R; Geisslinger G; Grösch S
    FASEB J; 2005 Aug; 19(10):1353-5. PubMed ID: 15946992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
    Behari J; Zeng G; Otruba W; Thompson MD; Muller P; Micsenyi A; Sekhon SS; Leoni L; Monga SP
    J Hepatol; 2007 May; 46(5):849-57. PubMed ID: 17275129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib-induced degradation of T-cell factors-1 and -4 in human colon cancer cells.
    Takahashi-Yanaga F; Yoshihara T; Jingushi K; Miwa Y; Morimoto S; Hirata M; Sasaguri T
    Biochem Biophys Res Commun; 2008 Dec; 377(4):1185-90. PubMed ID: 18983819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
    Maier TJ; Schilling K; Schmidt R; Geisslinger G; Grösch S
    Biochem Pharmacol; 2004 Apr; 67(8):1469-78. PubMed ID: 15041464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.
    Grösch S; Maier TJ; Schiffmann S; Geisslinger G
    J Natl Cancer Inst; 2006 Jun; 98(11):736-47. PubMed ID: 16757698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line.
    Xia JJ; Pei LB; Zhuang JP; Ji Y; Xu GP; Zhang ZP; Li N; Yan JL
    J Int Med Res; 2010; 38(4):1294-304. PubMed ID: 20926002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
    Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
    Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer.
    Tuynman JB; Vermeulen L; Boon EM; Kemper K; Zwinderman AH; Peppelenbosch MP; Richel DJ
    Cancer Res; 2008 Feb; 68(4):1213-20. PubMed ID: 18281498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells.
    Sakoguchi-Okada N; Takahashi-Yanaga F; Fukada K; Shiraishi F; Taba Y; Miwa Y; Morimoto S; Iida M; Sasaguri T
    Biochem Pharmacol; 2007 May; 73(9):1318-29. PubMed ID: 17270149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea polyphenol EGCG suppresses Wnt/β-catenin signaling by promoting GSK-3β- and PP2A-independent β-catenin phosphorylation/degradation.
    Oh S; Gwak J; Park S; Yang CS
    Biofactors; 2014; 40(6):586-95. PubMed ID: 25352148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lycopene synergistically enhances quinacrine action to inhibit Wnt-TCF signaling in breast cancer cells through APC.
    Preet R; Mohapatra P; Das D; Satapathy SR; Choudhuri T; Wyatt MD; Kundu CN
    Carcinogenesis; 2013 Feb; 34(2):277-86. PubMed ID: 23129580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.
    Bozzo F; Bassignana A; Lazzarato L; Boschi D; Gasco A; Bocca C; Miglietta A
    Chem Biol Interact; 2009 Dec; 182(2-3):183-90. PubMed ID: 19682443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
    Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
    Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells.
    Sinner D; Kordich JJ; Spence JR; Opoka R; Rankin S; Lin SC; Jonatan D; Zorn AM; Wells JM
    Mol Cell Biol; 2007 Nov; 27(22):7802-15. PubMed ID: 17875931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway.
    Zhang S; Da L; Yang X; Feng D; Yin R; Li M; Zhang Z; Jiang F; Xu L
    Toxicol Lett; 2014 Mar; 225(2):201-7. PubMed ID: 24374173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of peroxisome proliferator-activated receptor-beta/delta by the APC/beta-CATENIN pathway and nonsteroidal antiinflammatory drugs.
    Foreman JE; Sorg JM; McGinnis KS; Rigas B; Williams JL; Clapper ML; Gonzalez FJ; Peters JM
    Mol Carcinog; 2009 Oct; 48(10):942-52. PubMed ID: 19415698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
    Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
    J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib.
    Yamada Y; Yoshimi N; Hirose Y; Hara A; Shimizu M; Kuno T; Katayama M; Qiao Z; Mori H
    Jpn J Cancer Res; 2001 Jun; 92(6):617-23. PubMed ID: 11429049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual alterations in casein kinase I-epsilon and GSK-3beta modulate beta-catenin stability in hyperproliferating colonic epithelia.
    Umar S; Wang Y; Morris AP; Sellin JH
    Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G599-607. PubMed ID: 17053159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of GSK-3β in Regulation of Canonical Wnt/β-catenin Signaling and PI3-K/Akt Oncogenic Pathway in Colon Cancer.
    Jain S; Ghanghas P; Rana C; Sanyal SN
    Cancer Invest; 2017 Aug; 35(7):473-483. PubMed ID: 28718684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.